Progressive Multiple Sclerosis Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis
Verified date | April 2016 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Ministry of Health |
Study type | Interventional |
Primary Objective:
To assess the safety and tolerability of GZ402668 after ascending single intravenous (IV)
and subcutaneous (SC) doses in men and women with progressive multiple sclerosis.
Secondary Objectives:
To assess the following in men and women with progressive multiple sclerosis:
- The pharmacokinetic (PK) parameters of GZ402668 after ascending single IV doses.
- The pharmacodynamics (PD) of GZ402668 after ascending single IV doses.
- The PK parameters of GZ402668 after ascending single SC doses.
- The PD of GZ402668 after ascending single SC doses.
Status | Completed |
Enrollment | 48 |
Est. completion date | March 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion criteria: - Male or female adult with a diagnosis of progressive multiple sclerosis (MS) including primary progressive MS, secondary progressive MS, and progressive relapsing MS. - Aged between 18 and 65 years, inclusive. - Body weight greater than 40.0 kg. - Female patient of child bearing potential must use 2 highly effective contraception methods. - Male patient, whose partners are of childbearing potential (including lactating women), must accept to use, during sexual intercourse, 2 highly effective contraception methods. Male patient, whose partners are pregnant, must use, during sexual intercourse, a condom from the inclusion up to 4 months after investigational medicinal product administration. - Male patient who has agreed not to donate sperm for 4 months after product administration. Exclusion criteria: - Significant medical diseases or conditions, including poorly controlled hypertension, cardiovascular disease, inflammatory disorders, immunodeficiency, autoimmune disease, renal failure, liver dysfunction, cancer (except treated basal skin cell carcinoma), or active infection. - Frequent headaches and/or migraine, recurrent nausea and/or vomiting. - History or presence of drug or alcohol abuse. - Smoking more than 5 cigarettes or equivalent per day. - If female, pregnancy, lactating, or breast-feeding. - Patients with relapsing-remitting MS. - Lymphocyte counts below the lower limit of normal. - Treatment with natalizumab, methotrexate, azathioprine, or cyclosporine in the past 6 months. - Treatment with mitoxantrone, cyclophosphamide, cladribine, rituximab or any other immunosuppressant or cytotoxic therapy (other than steroids) in the last 12 months, or determined by the treating physician to have residual immune suppression from these treatments. - Treatment with glatiramer acetate or interferon beta in the past 4 weeks. - Treatment with fingolimod within the past 2 months. - Treatment with dimethyl fumarate in past 4 weeks. - Treatment with teriflunomide within the past 12 months unless patient has completed an accelerated clearance with cholestyramine. - Previous treatment with alemtuzumab. - Live, attenuated vaccine within 3 months prior to the randomization visit, such as varicella-zoster, oral polio, and rubella vaccines. - Clinically significant abnormality in thyroid function. - Inability to undergo magnetic resonance imaging with gadolinium administration. - Hypersensitivity or contraindication to acyclovir. - Known bleeding disorder. - Significant autoimmune disease. - Active infection or at high risk for infection. - Latent or active tuberculosis. - Major psychiatric disorder that is not adequately controlled by treatment. - Epileptic seizures that are not adequately controlled by treatment. - Prior history of invasive fungal infections. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Investigational Site Number 276001 | Berlin |
Lead Sponsor | Collaborator |
---|---|
Genzyme, a Sanofi Company |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with treatment emergent adverse events | 4 weeks | Yes | |
Secondary | maximum concentration (Cmax) | 4 weeks | No | |
Secondary | area under curve (AUC) | 4 weeks | No | |
Secondary | Number of participants with lymphocyte depletion | 4 weeks | No | |
Secondary | Number of participants with anti-drug antibodies | 4 weeks | Yes | |
Secondary | Number of participants with injection site reactions | 2 weeks | Yes | |
Secondary | Number of participants with corrected QT interval (QTcF) prolongation | 4 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02804594 -
A Study of Oxidative Pathways in MS Fatigue
|
Phase 2 | |
Completed |
NCT04120675 -
Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis
|
N/A | |
Completed |
NCT01719159 -
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis
|
Phase 2 | |
Enrolling by invitation |
NCT03552211 -
Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis
|
||
Recruiting |
NCT05740722 -
Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT03980145 -
G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis
|
N/A | |
Completed |
NCT03269071 -
Neural Stem Cell Transplantation in Multiple Sclerosis Patients
|
Phase 1 | |
Not yet recruiting |
NCT05811013 -
Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis
|
N/A | |
Not yet recruiting |
NCT04289909 -
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
|
N/A | |
Recruiting |
NCT05685784 -
Multiple Sclerosis Prediction and Monitoring of Progression Study
|
N/A | |
Completed |
NCT03493841 -
Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT03302806 -
Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis
|
||
Recruiting |
NCT05441488 -
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
|
Phase 3 | |
Recruiting |
NCT04695080 -
ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT06451159 -
A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT03423121 -
A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Terminated |
NCT02580669 -
Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis
|
N/A | |
Enrolling by invitation |
NCT05706220 -
Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
|
||
Recruiting |
NCT01815632 -
Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)
|
Phase 2 | |
Recruiting |
NCT01364246 -
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica
|
Phase 1/Phase 2 |